Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2016

View Archived Issues

CombiMatrix launches preimplantation genetic diagnosic test CombiPGD

Pfizer and Allergan announce termination of proposed merger agreement

Kamada initiates phase II study with intravenous alpha1-antitrypsin

Regeneron and MedImmune enter agreement to develop ADCs for the treatment of cancer

Bayer Schering Pharma patents factor XIa and KLKB1 inhibitors

AbbVie discloses HAT inhibitors

Ironwood Pharmaceuticals describes sGC activators

FORMA Therapeutics develops mutant-isocitrate dehydrogenase inhibitors

Epizyme presents lysine-specific demethylase inhibitors

Janssen and Tesaro announces global prostate cancer collaboration

PSMA1 shows potential as a prognostic biomarker for colon cancer

FDA grants orphan drug designation to 9-ING-41 for the treatment of glioblastoma

BIND Therapeutics reports topline data from phase II iNSITE 1 and 2 trials

Bristol-Myers Squibb's Opdivo approved in new indication in E.U.

TCF3 may be a useful biomarker to discriminate between seminomatous and non-seminomatous GCTs

MorphoSys and Galapagos begin clinical trials of MOR-106

Peptidream announces research agreement with BIND Therapeutics

Alpha Cancer's AFP assets for oncology and autoimmune diseases

SanBio cleared in Japan to conduct phase II trial of stem cell therapy

Pasireotide lowers plasma ACTH levels in patients with Nelson's syndrome

Allergan and Heptares announce commercialization agreement for novel neurologic disease therapies

Novartis' Revolade now approved for pediatric patients in E.U.

Afatinib approved in Europe for squamous cell carcinoma of the lung

Dako launches test for nivolumab survival benefit in non-squamous NSCLC